March 11 (Reuters) - Regenxbio ( RGNX ) said on
Wednesday that an interim data from a early-to-mid stage study
of its experimental gene therapy in patients with Duchenne
muscular dystrophy showed continued improvement in muscle
function and a clean safety profile.
(Reporting by Kamal Choudhury in Bengaluru)